Unlocking Value: Why Latin America is the Strategic Choice for Phase 1 Trials
Description
In this episode of the Driving the Business of Science podcast, Keith Parent, CEO of Court Square Group, interviews Sara Tylosky, CEO of Farmacon Global, about the Latin American market for clinical trials. Farmacon Global, a strategic partner with a network of physicians, focuses on rare diseases, oncology, and immunology in Latin America. Sara highlights the region's diversity, cost savings, and fast recruitment, noting that Latin America represents 0.7% of global phase 1 studies but has a population of more than 660 million and 30+ qualified sites. She addresses misconceptions about slow recruitment and regulatory issues, emphasizing the region's alignment with international guidelines and the potential for collaboration with CROs. Farmacon Global aims to expand its phase 1 research opportunities and educate biotechs on the region's benefits.
Interested in learning more about clinical trials in Latin America?
WEBINAR: Early Clinical Trials in LATAM: A Sustainable Data Strategy
United States
